Form 4: Moderna Director Sells Shares Under 10b5-1 Plan

Moderna, Inc. Director Abbas Hussain reported transactions involving the sale of common stock, executed under a pre-arranged trading plan.

Summary

• Director Abbas Hussain reported a transaction on April 30, 2026, where 16,233 restricted stock units converted into common stock.
• On May 1, 2026, Hussain sold 5,682 shares of common stock at a price of $46.63 per share.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on September 5, 2025.
• The sale was intended to cover tax liabilities arising from the vesting of restricted stock units.
• Following these transactions, Hussain beneficially owns 12,066 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While it involves a director selling shares, the transaction was conducted under a pre-arranged 10b5-1 plan to cover tax liabilities, which is a routine and expected event.

Positives

• The sale was executed under a Rule 10b5-1 plan, indicating pre-planned and potentially less market-impacting transactions.
• The sale was specifically to cover tax liabilities, a common and expected event for executives receiving stock awards.

Negatives

• Director Hussain sold a portion of his holdings, reducing his direct beneficial ownership.

Risks

• The sale of shares by a director could be perceived negatively by the market, potentially impacting share price, although it was conducted under a pre-arranged plan.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which details past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by Moderna's director is a common practice to manage stock sales in a way that avoids accusations of insider trading, especially for executives who have access to material non-public information.

Stakeholder Impact

• Shareholders: The sale, being under a 10b5-1 plan for tax purposes, is unlikely to have a significant negative impact on share price, but any insider selling can be a point of observation.

Next Steps

• Monitor future Form 4 filings for any additional transactions by Director Hussain or other insiders.
• Observe any market reaction to this reported transaction, although the 10b5-1 plan mitigates significant impact.

Key Dates

Keywords

Form 4, Moderna, MRNA, Insider Trading, Stock Sale, Restricted Stock Units, 10b5-1 Plan, Director Transaction, Beneficial Ownership